This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.
HSBC Sticks to Their Buy Rating for Wuxi Biologics (Cayman) (WXIBF)
HSBC analyst Linda Shu maintained a Buy rating on Wuxi Biologics (Cayman) yesterday and set a price target of HK$45.00. The company’s shares closed last Tuesday at $4.90.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Shu covers the Healthcare sector, focusing on stocks such as Pharmaron Beijing Co., Ltd. Class H, Wuxi Biologics (Cayman), and Hangzhou Tigermed Consulting Co., Ltd. Class H. According to TipRanks, Shu has an average return of 17.7% and a 72.73% success rate on recommended stocks.
Currently, the analyst consensus on Wuxi Biologics (Cayman) is a Strong Buy with an average price target of $4.86.
WXIBF market cap is currently $20.52B and has a P/E ratio of 34.07.
This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.
